Fidelity Investments
CAPR icon

Fidelity Investments’s Capricor Therapeutics CAPR Stock Holding History

Fidelity Investments’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.32M Sell
138,986
-998,744
-88% -$11.1M ﹤0.01% 2936
2026
Q2 		$27.4M Buy
1,137,730
+365,081
+47% +$11.1M ﹤0.01% 1755
2026
Q1 		$23.5M Sell
772,649
-149,985
-16% -$4M ﹤0.01% 1722
2025
Q4 		$26.6M Buy
922,634
+898,944
+3,795% +$11.7M ﹤0.01% 1673
2025
Q3 		$171K Sell
23,690
-500
-2% -$3.68K ﹤0.01% 3425
2025
Q2 		$240K Sell
24,190
-566
-2% -$5.98K ﹤0.01% 3241
2025
Q1 		$235K Buy
24,756
+949
+4% +$13.2K ﹤0.01% 3184
2024
Q4 		$329K Sell
23,807
-537
-2% -$9.41K ﹤0.01% 3071
2024
Q3 		$370K Buy
+24,344
New +$120K ﹤0.01% 2982
2024
Q2 		– Sell
-1
Closed -$7 – 5394
2024
Q1 		$7 Buy
+1
New +$5 ﹤0.01% 5286
2021
Q4 		– Sell
-40
Closed – – 4374
2021
Q3 		$0 Hold
40
– – ﹤0.01% 4391
2021
Q2 		$0 Sell
40
-185
-82% -$784 ﹤0.01% 4284
2021
Q1 		$1K Buy
+225
New +$1.3K ﹤0.01% 3805

Other funds holding CAPR

UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
HBK Sorce Advisory
HBK Sorce Advisory Erie, Pennsylvania $5.18B AUM 12.38% 1-Year Est. Return
Oppenheimer & Co
Oppenheimer & Co New York $9.5B AUM 27.65% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $73.3B AUM 63.67% 1-Year Est. Return

Fidelity Investments's CAPR Position: Q3 2026 in Review

Fidelity Investments reduced its Capricor Therapeutics (CAPR) stake by 88% in Q3 2026, selling an estimated $11.1M and leaving 138,986 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #2936.

Fidelity Investments first reported a position in CAPR in Q1 2021 and has held it in 13 quarters since. The position peaked at $27.4M in Q2 2026. 62 funds tracked by Wall St. Rank hold CAPR as of Q3 2026.

  • Fidelity Investments held 138,986 shares of Capricor Therapeutics worth $1.32M as of Q3 2026.
  • Fidelity Investments sold 998,744 Capricor Therapeutics shares in Q3 2026, an estimated $11.1M.
  • Capricor Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q3 2026, its #2936 holding.
  • Fidelity Investments first reported a position in Capricor Therapeutics in Q1 2021 and has held it in 13 quarters since.
  • Fidelity Investments's Capricor Therapeutics position peaked at $27.4M in Q2 2026.
  • 62 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2026.

Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.